The effect of bevacizumab on tumour growth of malignant fibrous histiocytoma in an animal model

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3391-3395

  Okada, Yoshiyuki ^a   Akisue, Toshihiro ^a   Hara, Hitomi ^a   Kishimoto, Kenta ^a   Kawamoto, Teruya ^a   Imabori, Masaya ^b   Kishimoto, Shin Ichiro ^a   Fukase, Naomasa ^a   Onishi, Yasuo ^a   Kurosaka, Masahiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO CANCER CENTER   (Japan)

Author keywords

Bevacizumab; MFH; VEGF

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLANT EXTRACT; U & D SWEET BITTER;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; DRUG ACTIVITY; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG SCREENING; HISTIOCYTOMA, MALIGNANT FIBROUS; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PLANT EXTRACTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77958557976     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505-515, 2000.
2. Darland DC and DAmore PA: Blood vessel maturation: vascular development comes of age. J Clin Invest 103: 157-158, 1999.
3. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
4. Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997.
5. Mattern J, Koomagi R and Volm M: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 73: 931-934, 1996.
6. Yoshiji H, Gomez DE, Shibuya M and Thorgeirsson UP: Expression of vascular endothelial growth factor, its receptors, and other angiogenic factors in breast cancer. Cancer Res 56: 2013-2016, 1996
7. Olson TA, Mohanraj D, Carson LF and Ramakrishnan S: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54: 276-280, 1994
8. Hara H, Akisue T, Fujimoto T, Imabori M, Kawamoto T, Kuroda R, Fujioka H, Yamamoto T, Doita M and Kurosaka M: Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. Anticancer Res 26: 4307-4311, 2006.
9. Gerber HP and Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680, 2005.
10. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF and Kabbinavar F: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508, 2005.
11. Kiyozuka Y, Nakagawa H, Uemura Y, Senzaki H, Yamamoto A, Noguchi T, Mizuta H, Nakanishi K, Nakano S and Tsubura A: Novel cell lines established from a human myxoid malignant fibrous histiocytoma arising in the uterus. Cancer Genet Cytogenet 127: 7-15, 2001.
12. Gimbrone MA, Leapman SB, Cotran RS and Folkman J: Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136: 261-276, 1972.
13. Conway EM, Collen D and Carmeliet P: Molecular mechanisms of blood vessel growth. Cardiovasc Res 49: 507-521, 2001.
14. Rosenblatt MI and Azar DT: Anti-angiogenic therapy: prospects for treatment of ocular tumors. Semin Ophthalmol 21: 151-160, 2006. (Pubitemid 44266789)
15. Bergsland EK: Update on clinical trials targeting vascular endothelial growth factor in cancer. Am J Health Syst Pharm 61: S12-S20, 2004.
16. Argyriou AA and Kalofonos HP: Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Mol Med 15: 183-191, 2009.
17. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.
18. Dalai S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, Lewis IJ, Johnston C, Laurence V and Burchill SA: Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 11: 2364-2378, 2005.
19. Asano M, Yukita A, Matsumoto T, Kondo S and Suzuki H: Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to vascular endothelial growth factor/vascular permeability factor. Cancer Res 55: 5296-5301, 1995
20. Borgström P, Hillan KJ, Sriramarao P and Ferrara N: Complete inhibition of angiogenesis and growth of microtumors by antivascular endothelial growth factor neutralizing antibodies. Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56: 4032-4039, 1996.
21. Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, Ryffel B, Bensussan A, Bizzini B, Gallo RC, Zagury D and Uzan G: VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 104: 2837-2842, 2007.
22. Gerber HP, Kowalski J, Sherman D, Eberhard DA and Ferrara N: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60: 6253-6258, 2000.
23. Fujita K, Sano D, Kimura M, Yamashita Y, Kawakami M, Ishiguro Y, Nishimura G, Matsuda H and Tsukuda M: Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 18: 47-51, 2007.
24. Prichard CN, Kim S, Yazici YD, Doan DD, Jasser SA, Mandai M and Myers JN: Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 117: 674-679, 2007.
25. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI and Agus DB: Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 8: 3226-3231, 2002.
26. Li Q, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y and Sone S: The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 13: 5918-2595, 2007.
27. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K and Yao JC: Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109: 1478-1486, 2007.
28. Amato RJ: Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16: 7-15, 2005.
29. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D: Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13: 1845-1857, 2006.
30. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989, 2001.